Abcuro, Inc (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Abcuro, Inc

Developing immunotherapies for autoimmune diseases and cancer

Founded 2015 43 employees Series B Total: $214.85M Biotechnology, Health Care +1

Abcuro, Inc is a clinical stage biotechnology company founded in 2015 that focuses on developing immunotherapies for autoimmune diseases and cancer. The company is known for its flagship products ABC008 and ABC015, both of which target cytotoxic T and NK cells expressing the inhibitory immune checkpoint receptor KLRG1. ABC008, a first-in-class anti-KLRG1 antibody, aims to deplete cytotoxic T cells attacking healthy muscle tissue in patients with inclusion body myositis (IBM), a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. The noteworthy achievement is obtaining FDA orphan drug designation for ABC008 in IBM. On the other hand, ABC015, the company's anti-KLRG1 blocking antibody, is designed to reactivate inhibited cytotoxic T and NK cells in the tumor microenvironment. This holds significant promise in the realm of cancer treatment and underscores Abcuro's potential in addressing unmet medical needs. The most recent development for Abcuro, Inc is the $155.00M Series B investment which was secured on 17 August 2023. The investment involved notable backers such as Pontifax, RA Capital Management, BlackRock, Redmile Group, Samsara BioCapital, Sanofi Ventures, Soleus Capital, Mass General Brigham Ventures, Eurofarma, and Bain Capital Life Sciences. Abcuro's dedication to advancing treatments for autoimmune and cancer indications, coupled with its strategic partnerships and significant funding, positions the company as a compelling player in the biotechnology and healthcare industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	••••••	10	•••• ••••	17 Aug 2023
Series A	••••••	-		07 Jan 2021
Venture Round	••••••	-		06 Jul 2020
Series A	••••••	-		09 Nov 2018
Seed Round	••••••	-		13 Dec 2016

Funding Stage

Amount

Investors

Lead Investors

Date

Series B

••••••

•••• ••••

17 Aug 2023

Series A

••••••

07 Jan 2021

Venture Round

••••••

06 Jul 2020

Series A

••••••

09 Nov 2018

Seed Round

••••••

13 Dec 2016

FAQ About Abcuro, Inc

Developing immunotherapies for autoimmune diseases and cancer

Abcuro, Inc was founded in 2015.

Abcuro, Inc operates in the following industries: Biotechnology, Health Care, Health and Wellness.

Abcuro, Inc has approximately 43 employees.

Abcuro, Inc has completed 5 funding rounds, raising a total of $214.85M. The latest funding stage is Series B.

Top alternatives and competitors to Abcuro, Inc include Acepodia, Mersana Therapeutics, Corbus Pharmaceuticals, Illimis Therapeutics, CytoDyn. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Abcuro, Inc and Acepodia are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Abcuro, Inc

General Information

Track Abcuro, Inc

Discover More

About Abcuro, Inc

Funding Rounds & Investors (5)

Abcuro, Inc Alternatives & Competitors

FAQ About Abcuro, Inc

Don't just browse. Track.